Metabolic Disorder in Alzheimer's Disease

Overview

Journal Metab Brain Dis

Publisher Springer

Specialties Endocrinology
Neurology

Date 2021 Feb 27

PMID 33638805

Citations 12

Authors

Mrinal K Poddar

Soumyabrata Banerjee

Apala Chakraborty

Debasmita Dutta

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD), a well known aging-induced neurodegenerative disease is related to amyloid proteinopathy. This proteinopathy occurs due to abnormalities in protein folding, structure and thereby its function in cells. The root cause of such kind of proteinopathy and its related neurodegeneration is a disorder in metabolism, rather metabolomics of the major as well as minor nutrients. Metabolomics is the most relevant "omics" platform that offers a great potential for the diagnosis and prognosis of neurodegenerative diseases as an individual's metabolome. In recent years, the research on such kinds of neurodegenerative diseases, especially aging-related disorders is broadened its scope towards metabolic function. Different neurotransmitter metabolisms are also involved with AD and its associated neurodegeneration. The genetic and epigenetic backgrounds are also noteworthy. In this review, the physiological changes of AD in relation to its corresponding biochemical, genetic and epigenetic involvements including its (AD) therapeutic aspects are discussed.

Citing Articles

Dual orexin receptor antagonists as promising therapeutics for Alzheimer's disease.

Ragsdale S, Radovich J, Coiduras I, McCall W, Grant S, Lee C NPJ Biol Timing Sleep. 2025; 2(1):11.

PMID: 40066297 PMC: 11890173. DOI: 10.1038/s44323-025-00025-5.

The Role of the Urea Cycle in the Alzheimer's Disease Brain.

Al-Thani N, Stewart G, Costello D J Neurochem. 2025; 169(3):e70033.

PMID: 40022483 PMC: 11871420. DOI: 10.1111/jnc.70033.

Investigating the neuroprotective effects of extract and its effect on metabolomic profile of rat model of sporadic Alzheimer's disease.

Talebi M, Ayatollahi S, AsHabi M, Kobarfard F, Khoramjouy M, Boroujeni F Heliyon. 2025; 11(3):e42412.

PMID: 39981356 PMC: 11840490. DOI: 10.1016/j.heliyon.2025.e42412.

A narrative review of phase III and IV clinical trials for the pharmacological treatment of Huntington's disease in adults.

Alharthi M Medicine (Baltimore). 2025; 103(52):e41073.

PMID: 39969346 PMC: 11688028. DOI: 10.1097/MD.0000000000041073.

Neuroprotective Effects of Dehydroepiandrosterone and Hericium erinaceus in Scopolamine-induced Alzheimer's Diseases-like Symptoms in Male Rats.

Shirvani M, Nouri F, Sarihi A, Habibi P, Mohammadi M Cell Biochem Biophys. 2024; 82(3):2853-2864.

PMID: 38990419 DOI: 10.1007/s12013-024-01400-y.

References

Aisen P, Touchon J, Amariglio R, Andrieu S, Bateman R, Breitner J . EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials. J Prev Alzheimers Dis. 2017; 4(2):116-124. PMC: 5724787. DOI: 10.14283/jpad.2017.13. View

Alkalay A, Rabinovici G, Zimmerman G, Agarwal N, Kaufer D, Miller B . Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load. Curr Alzheimer Res. 2012; 10(1):48-56. PMC: 3768143. View

Antunez C, Boada M, Gonzalez-Perez A, Gayan J, Ramirez-Lorca R, Marin J . The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer's disease. Genome Med. 2011; 3(5):33. PMC: 3219074. DOI: 10.1186/gm249. View

Arendt T . Synaptic degeneration in Alzheimer's disease. Acta Neuropathol. 2009; 118(1):167-79. DOI: 10.1007/s00401-009-0536-x. View

Arnold S, Arvanitakis Z, Macauley-Rambach S, Koenig A, Wang H, Ahima R . Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. 2018; 14(3):168-181. PMC: 6098968. DOI: 10.1038/nrneurol.2017.185. View

Banerjee S, Poddar M . Carnosine: effect on aging-induced increase in brain regional monoamine oxidase-A activity. Neurosci Res. 2014; 92:62-70. DOI: 10.1016/j.neures.2014.09.009. View

Banerjee S, Ghosh T, Poddar M . Carnosine reverses the aging-induced down regulation of brain regional serotonergic system. Mech Ageing Dev. 2015; 152:5-14. DOI: 10.1016/j.mad.2015.09.002. View

Bateman R, Xiong C, Benzinger T, Fagan A, Goate A, Fox N . Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012; 367(9):795-804. PMC: 3474597. DOI: 10.1056/NEJMoa1202753. View

Bedard K, Krause K . The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007; 87(1):245-313. DOI: 10.1152/physrev.00044.2005. View

10.

Berchtold N, Coleman P, Cribbs D, Rogers J, Gillen D, Cotman C . Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer's disease. Neurobiol Aging. 2013; 34(6):1653-61. PMC: 4022280. DOI: 10.1016/j.neurobiolaging.2012.11.024. View

11.

Berg A, Scherer P . Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005; 96(9):939-49. DOI: 10.1161/01.RES.0000163635.62927.34. View

12.

Bieschke J . Natural compounds may open new routes to treatment of amyloid diseases. Neurotherapeutics. 2013; 10(3):429-39. PMC: 3701768. DOI: 10.1007/s13311-013-0192-7. View

13.

Bohnen N, Kaufer D, Hendrickson R, Ivanco L, Lopresti B, Davis J . Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. Neurosci Lett. 2005; 380(1-2):127-32. DOI: 10.1016/j.neulet.2005.01.031. View

14.

Boldrini M, Fulmore C, Tartt A, Simeon L, Pavlova I, Poposka V . Human Hippocampal Neurogenesis Persists throughout Aging. Cell Stem Cell. 2018; 22(4):589-599.e5. PMC: 5957089. DOI: 10.1016/j.stem.2018.03.015. View

15.

Bossers K, Wirz K, Meerhoff G, Essing A, van Dongen J, Houba P . Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. Brain. 2010; 133(Pt 12):3699-723. DOI: 10.1093/brain/awq258. View

16.

Bottiglieri T, Godfrey P, Flynn T, Carney M, Toone B, Reynolds E . Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry. 1990; 53(12):1096-8. PMC: 488323. DOI: 10.1136/jnnp.53.12.1096. View

17.

Bourre J, Pascal G, Durand G, Masson M, Dumont O, Piciotti M . Alterations in the fatty acid composition of rat brain cells (neurons, astrocytes, and oligodendrocytes) and of subcellular fractions (myelin and synaptosomes) induced by a diet devoid of n-3 fatty acids. J Neurochem. 1984; 43(2):342-8. DOI: 10.1111/j.1471-4159.1984.tb00906.x. View

18.

Braak H, Braak E . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. DOI: 10.1007/BF00308809. View

19.

Braak H, Thal D, Ghebremedhin E, Del Tredici K . Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011; 70(11):960-9. DOI: 10.1097/NEN.0b013e318232a379. View

20.

Braskie M, Thompson P . Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings. Trends Cogn Sci. 2013; 17(10):510-6. PMC: 3947610. DOI: 10.1016/j.tics.2013.08.007. View